527 people without comorbidities died from Covid-19 in Malaysia this year up to June 19, or about 14% of 3,877 total fatalities.
May and the first 19 days of June saw a steep increase in Covid deaths at 1,290 and 1,552 fatalities respectively, along with non-comorbid deaths.
Of the 527 people without underlying health conditions who died from Covid-19 this year up to June 19, nearly 85% were Malaysians.
The highest rate of Covid-19 deaths without comorbidities this year up to June 19:
- Labuan (261 deaths per million population)
- KL (43)
- Melaka (26)
- Selangor (25)
- Negeri Sembilan (20)
The highest proportion of Covid-19 deaths without comorbidities this year (up to June 19) was among those aged 15-24 at 31%, or 4 of 13 total fatalities.
More Covid-19 fatalities w/o comorbidities, however, were recorded at 103 and 244 deaths in the 55-64 and ≥65 respectively.
The highest proportion of Covid brought-in-dead without comorbidities was reported in the 15-24 age group at 15%, or 2 of 13 total deaths.
But higher numbers of BID w/o comorbidities were recorded among people aged ≥65 years at 52 deaths, followed by 45-54 age grp (41 deaths).
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Malaysia's current medicine shortage isn't like previous "minor" perennial drug shortages, when certain meds tend to run out towards end of the year because of low funding.
This time, the med shortage may be far more critical & extensive because of global supply disruptions. 🧵
Malaysia is a net pharmaceutical importer.
This makes us extremely vulnerable to global supply disruptions caused by Covid pandemic, worsened by China lockdowns in 2022, and the Russia-Ukraine war that disrupted global supply chains across goods (not just pharmaceuticals).
Malaysia's entire supply of finished pharmaceutical products is either:
a) Directly imported
b) Indirectly imported via import of active pharmaceutical ingredients [APIs] (the active component of a drug), plus pharmaceutical intermediates and excipients (other components)
Agreements disclosed in a second lawsuit involving MySJ Sdn Bhd -- board power struggle -- show that MySJ owns the MySejahtera app, IP rights, and platform, while Entomo owns software used to develop the app.
Aug 2021 share sale agreement states MySJ is negotiating to acquire a health care management services company and a digital health care platform services company.
Mudah Healthcare & AmanInsure named in meeting minutes.
Both located in same address next to Entomo/MySJ's office.
AmanInsure Sdn Bhd's site even has mock-ups of MySejahtera with Covid-19 insurance/ takaful button (which scared me initially because AmanInsure didn't call it "mock-ups", but called it "User Journey).
Govt claims MySejahtera app/ IP ownership, but a private company can do this.
How @codebluenews broke the MySejahtera controversy: 🧵
PAC tabled its 2nd Covid vaccine procurement report on March 24. My colleague @alifahzndn spotted it in the Order Paper.
(CodeBlue checks Parliament order papers and replies to spot any bills/ answers related to health).
At that time, PAC chair @wongkahwoh didn't issue a statement about the release of PAC's Covid vaccine procurement report (should be done for reports in future).
This Pharmaniaga statement -- which MOH's ICR denounced as having "misrepresented" facts and evidence -- failed to mention that the Yale study did NOT compare Sinovac vs Pfizer boosters and that two Sinovac doses showed no "detectable" neutralizing antibodies against Omicron.
A Pfizer booster did elicit "detectable" neutralization against Omicron for double-vax Sinovac recipients, but only increased protection to similar levels as 2 Pfizer jabs.
In other words, 2 Sinovac + 1 Pfizer = 2 Pfizer.
NOT that a Sinovac booster is better than Pfizer booster
Hence why one of the authors of the Yale-Dominican Republic study suggested that Sinovac recipients may need two boosters to protect against Omicron, instead of one.
Because 1 Pfizer booster + 2 Sinovac doses only raises protection to 2 mRNA doses.
It is extremely deceptive to give the impression that a Pfizer booster for Sinovac recipients is less effective against Omicron and to put up another completely unrelated study to imply that a Sinovac booster is better than a Pfizer booster for Sinovac recipients.
If you want to talk about a research study on Sinovac alone, then don't headline your statement on another completely unrelated study.
Btw no company in the life sciences puts down another company's products.